Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Liou JP
------>authors3_c=
------>paper_class1=6
------>Impact_Factor=None
------>paper_class3=0
------>paper_class2=0
------>vol=
------>confirm_bywho=amel
------>insert_bywho=jpl
------>Jurnal_Rank=None
------>authors4_c=
------>comm_author=
------>patent_EDate=2026-08-31 00:00:00
------>authors5_c=
------>publish_day=1
------>paper_class2Letter=None
------>page2=
------>medlineContent=
------>unit=G0100
------>insert_date=20090924
------>iam=1
------>update_date=None
------>author=???
------>change_event=4
------>ISSN=
------>authors_c=
------>score=15
------>journal_name=95132140
------>paper_name=Indoline-sulfonamide compounds
------>confirm_date=20090925
------>tch_id=093131
------>pmid=17660383
------>page1=
------>fullAbstract=We have previously synthesized a series of 7-aroylaminoindoline-1-sulfonamides as a novel class of antitubulin agents. Here we show that one of these new compounds, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), is potently effective against various resistant and nonresistant cancer cell lines despite the status of multidrug resistance, multidrug-resistance associated protein, or other resistance factors in vitro. J30 inhibits assembly of purified tubulin by strongly binding to the colchicine-binding site. Western blot and immunofluorescence experiments demonstrate that J30 depolymerizes microtubules in the KB cell line, resulting in an accumulation of G2/M phase cells. Further studies indicate that J30 causes cell cycle arrest, as assessed by flow analyses and the appearance of MPM-2 (a specific mitotic marker), and is associated with up-regulation of cyclin B1, phosphorylation of Cdc25C, and dephosphorylation of Cdc2. J30 also causes Bcl-2 phosphorylation, cytochrome c translocation, and activation of the caspase-9 and caspase-3 cascades. These findings suggest that the J30-mediated apoptotic signaling pathway depends on caspases and mitochondria. Finally, we show that oral administration of J30 significantly inhibits tumor growth in NOD/scid mice bearing human oral, gastric, and drug-resistant xenografts. Together, our results suggest that J30 has potential as a chemotherapeutic agent for treatment of various malignancies.
------>tmu_sno=None
------>sno=22303
------>authors2=Chang JY
------>authors3=Hsieh HP
------>authors4=
------>authors5=
------>authors6=
------>authors6_c=
------>authors=Liou JP
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=
------>publish_area=0
------>updateTitle=A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H-indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule.
------>language=1
------>check_flag=None
------>submit_date=None
------>country=????
------>no=
------>patent_SDate=2006-08-31 00:00:00
------>update_bywho=None
------>publish_year=2009
------>submit_flag=None
------>publish_month=1
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z